|Articles|November 16, 2020
- Pharmaceutical Executive-11-01-2020
- Volume 40
- Issue 11
Pharmaceutical Executive, November 2020 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive November 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 5 years ago
Synthetic Biology and the Environmentabout 5 years ago
Measuring Pharma’s Wider Mandateabout 5 years ago
Patients as the North Starabout 5 years ago
A Rare-Disease Must? Building Long-Term Relationshipsabout 5 years ago
Making Remote Work a Success Beyond COVIDabout 5 years ago
CRISPR for Diversity, and Humanity’s, Sakeabout 5 years ago
Expediting the Cancer Treatment Pathabout 5 years ago
Vaccine Authorization, Distribution Raise Multiple Challengesabout 5 years ago
EU Leaders in High-Stakes Gamble on COVID ResponsesNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients
2
Report: FDA to Change Vaccine Approval Process Based on Agency’s Claim of Covid Vaccine-Related Deaths
3
Korea and Australia's P&MA Shift: From Local Launch Opportunities to Regional Blueprint
4
Pharmaceutical Executive Daily: U.S. & U.K. Agree to 0% Tariffs on Pharmaceutical Products
5
